The opportunity

Respiratory disease affects one in five people in England and is the third biggest cause of death, yet waiting times to access diagnostic tests, particularly in the most deprived areas, are increasingly long. AstraZeneca and their partner Health Innovation Manchester saw an opportunity to explore whether new home testing technology could provide accurate and timely support to diagnose COPD or asthma.

 

The result

We designed, built, and tested a prototype for a brand-new remote spirometry screening service called Aspire, gaining a comprehensive understanding of the experiences of both patients and healthcare professionals navigating the end-to-end service. The insights gathered from this phase identified several opportunities to develop the prototype service so that it could be scaled up to serve 1,000 patients in Phase 2.